Virtus Biotech Clinical Trials ETF
19 hedge funds and large institutions have $10.2M invested in Virtus Biotech Clinical Trials ETF in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
149% more capital invested
Capital invested by funds: $4.08M → $10.2M (+$6.08M)
58% more funds holding
Funds holding: 12 → 19 (+7)
9.29% more ownership
Funds ownership: 23.02% → 32.31% (+9.3%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCP
Kera Capital Partners
San Jose,
California
|
+$2.89M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.39M |
| 3 |
MML Investors Services
Springfield,
Massachusetts
|
+$507K |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
+$429K |
| 5 |
Morgan Stanley
New York
|
+$208K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$859K |
| 2 |
MCP
Militia Capital Partners
Las Vegas,
Nevada
|
-$758K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$428K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$99K |
| 5 |
LPL Financial
San Diego,
California
|
-$4.92K |
BBC Hedge Fund Activity: Q4 2025 in Review
19 of the 8,280 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q4 2025, worth a combined $10.2M — up 149% from $4.08M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new BBC positions and 2 closed out — a net gain of 7 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Kera Capital Partners, opening a new position worth an estimated $2.89M. The largest seller was Jane Street, cutting an estimated $859K.
- 19 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q4 2025, up from 12 in Q3 2025.
- Funds reported $10.2M of Virtus Biotech Clinical Trials ETF stock for Q4 2025, up 149% quarter-over-quarter.
- 9 funds opened new Virtus Biotech Clinical Trials ETF positions in Q4 2025 and 2 closed out, a net change of +7 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q4 2025 was Kera Capital Partners, an estimated $2.89M added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q4 2025 was Jane Street, an estimated $859K sold.
Based on aggregated 13F filings for Q4 2025.